Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata.

Détails

Ressource 1Télécharger: 28831086_BIB_26C4A26464DA.pdf (1364.66 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_26C4A26464DA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata.
Périodique
Scientific reports
Auteur⸱e⸱s
Vella A., De Carolis E., Mello E., Perlin D.S., Sanglard D., Sanguinetti M., Posteraro B.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Statut éditorial
Publié
Date de publication
22/08/2017
Peer-reviewed
Oui
Volume
7
Numéro
1
Pages
9099
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
The echinocandins are relatively new antifungal drugs that represent, together with the older azoles, the recommended and/or preferred agents to treat candidaemia and other forms of invasive candidiasis in human patients. If "time is of the essence" to reduce the mortality for these infections, the administration of appropriate antifungal therapy could be accelerated by the timely reporting of laboratory test results. In this study, we attempted to validate a MALDI-ToF mass spectrometry-based assay for the antifungal susceptibility testing (AFST) of the potentially multidrug-resistant pathogen Candida glabrata against anidulafungin and fluconazole. The practical applicability of the assay, reported here as MS-AFST, was assessed with a panel of clinical isolates that were selected to represent phenotypically and genotypically/molecularly susceptible or resistant strains. The data show the potential of our assay for rapid detection of antifungal resistance, although the MS-AFST assay performed at 3 h of the in vitro antifungal exposure failed to detect C. glabrata isolates with echinocandin resistance-associated FKS2 mutations. However, cell growth kinetics in the presence of anidulafungin revealed important cues about the in vitro fitness of C. glabrata isolates, which may lead to genotypic or phenotypic antifungal testing in clinical practice.
Mots-clé
Anidulafungin/pharmacology, Anidulafungin/therapeutic use, Antifungal Agents/pharmacology, Antifungal Agents/therapeutic use, Candida glabrata/drug effects, Candida glabrata/genetics, Candida glabrata/growth & development, Candidiasis, Invasive/drug therapy, Candidiasis, Invasive/microbiology, Drug Resistance, Fungal, Fluconazole/pharmacology, Fluconazole/therapeutic use, Fungal Proteins/genetics, Genetic Fitness, Glucosyltransferases/genetics, Humans, Microbial Sensitivity Tests, Microbial Viability/drug effects, Mutation, Phenotype, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/09/2017 18:45
Dernière modification de la notice
20/08/2019 14:05
Données d'usage